MXPA03011022A - Derivados de urea con actividad antiproteolitica. - Google Patents
Derivados de urea con actividad antiproteolitica.Info
- Publication number
- MXPA03011022A MXPA03011022A MXPA03011022A MXPA03011022A MXPA03011022A MX PA03011022 A MXPA03011022 A MX PA03011022A MX PA03011022 A MXPA03011022 A MX PA03011022A MX PA03011022 A MXPA03011022 A MX PA03011022A MX PA03011022 A MXPA03011022 A MX PA03011022A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- formula
- factor viia
- urea derivatives
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invencion se refiere a los compuestos de la formula I: en la cual R1, R2, R4, R5, D1, D2, X1, X2, X3, A y B tienen los significados que se indican en las reivindicaciones. Los compuestos de la formula I son compuestos con actividad farmacologica valiosos. Estos muestran un fuerte efecto antitrombotico y son convenientes, por ejemplo, para el tratamiento y profilaxis de enfermedades tromboembolicas y restenosis. Son inhibidores reversibles de la enzima de coagulacion sanguinea el factor VIIa y en general pueden aplicarse en estados en los cuales esta presente una actividad no deseada del factor VIIa, o para la curacion o prevencion de los cuales se pretende la inhibicion del factor VIIa. La invencion ademas se refiere a los procesos para la preparacion de los compuestos de la formula I, su uso, en particular como ingredientes activos en farmaceuticos, y las preparaciones farmaceuticas que los contienen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01115353A EP1270551A1 (en) | 2001-06-26 | 2001-06-26 | Urea derivatives with antiproteolytic activity |
| PCT/EP2002/006422 WO2003002524A2 (en) | 2001-06-26 | 2002-06-12 | Urea derivatives with antiproteolytic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03011022A true MXPA03011022A (es) | 2004-03-19 |
Family
ID=8177820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03011022A MXPA03011022A (es) | 2001-06-26 | 2002-06-12 | Derivados de urea con actividad antiproteolitica. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6706715B2 (es) |
| EP (2) | EP1270551A1 (es) |
| JP (1) | JP4231403B2 (es) |
| AT (1) | ATE338746T1 (es) |
| AU (1) | AU2002325238A1 (es) |
| CA (1) | CA2451206C (es) |
| CY (1) | CY1105751T1 (es) |
| DE (1) | DE60214569T2 (es) |
| DK (1) | DK1423357T3 (es) |
| ES (1) | ES2269750T3 (es) |
| MX (1) | MXPA03011022A (es) |
| PE (1) | PE20030133A1 (es) |
| PT (1) | PT1423357E (es) |
| WO (1) | WO2003002524A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120104619A (ko) * | 2003-08-14 | 2012-09-21 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물 |
| BRPI0510295A (pt) | 2004-05-04 | 2007-11-06 | Novo Nordisk Healthcare Ag | preparação de uma glicoproteìna, e, método para produzir a mesma |
| WO2005113534A2 (en) | 2004-05-12 | 2005-12-01 | Schering Corporation | Cxcr1 and cxcr2 chemokine antagonists |
| EP1855722A2 (en) * | 2005-02-24 | 2007-11-21 | Novo Nordisk Health Care AG | Compounds for stabilizing factor vii polypeptide formulations |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| WO2007022964A2 (de) | 2005-08-24 | 2007-03-01 | Abbott Gmbh & Co. Kg | Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| TW200908984A (en) * | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| WO2010009139A2 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Imidazolyl pyrimidine inhibitor compounds |
| AU2009271019A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| MX2011001090A (es) | 2008-07-28 | 2011-03-15 | Gilead Sciences Inc | Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno. |
| MX2011013166A (es) | 2009-06-08 | 2012-01-30 | Gilead Sciences Inc | Compuestos inhibidores de hdac de cicloalquilcarbamatobenzamida-an ilina. |
| EP2440519A1 (en) | 2009-06-08 | 2012-04-18 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| MX2016008022A (es) | 2013-12-20 | 2017-05-10 | Saudi Basic Ind Corp | Sistema catalizador para polimerizacion de una olefina. |
| US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| SI3571193T1 (sl) | 2017-01-23 | 2022-04-29 | Cadent Therapeutics, Inc. | Modulatorji kalijevega kanalčka |
| JP2022508945A (ja) | 2018-10-22 | 2022-01-19 | カデント セラピューティクス，インコーポレーテッド | カリウムチャネルモジュレーターの結晶形態 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5314902A (en) * | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
| DE4309867A1 (de) * | 1993-03-26 | 1994-09-29 | Cassella Ag | Neue Harnstoffderivate, ihre Herstellung und Verwendung |
| EP0987274A1 (en) * | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
-
2001
- 2001-06-26 EP EP01115353A patent/EP1270551A1/en not_active Withdrawn
-
2002
- 2002-06-12 AT AT02758230T patent/ATE338746T1/de active
- 2002-06-12 ES ES02758230T patent/ES2269750T3/es not_active Expired - Lifetime
- 2002-06-12 CA CA2451206A patent/CA2451206C/en not_active Expired - Fee Related
- 2002-06-12 EP EP02758230A patent/EP1423357B1/en not_active Expired - Lifetime
- 2002-06-12 JP JP2003508707A patent/JP4231403B2/ja not_active Expired - Fee Related
- 2002-06-12 AU AU2002325238A patent/AU2002325238A1/en not_active Abandoned
- 2002-06-12 DE DE60214569T patent/DE60214569T2/de not_active Expired - Lifetime
- 2002-06-12 WO PCT/EP2002/006422 patent/WO2003002524A2/en active IP Right Grant
- 2002-06-12 PT PT02758230T patent/PT1423357E/pt unknown
- 2002-06-12 DK DK02758230T patent/DK1423357T3/da active
- 2002-06-12 MX MXPA03011022A patent/MXPA03011022A/es active IP Right Grant
- 2002-06-26 PE PE2002000570A patent/PE20030133A1/es not_active Application Discontinuation
- 2002-06-26 US US10/183,848 patent/US6706715B2/en not_active Expired - Lifetime
-
2006
- 2006-11-02 CY CY20061101577T patent/CY1105751T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002325238A1 (en) | 2003-03-03 |
| ATE338746T1 (de) | 2006-09-15 |
| DE60214569D1 (de) | 2006-10-19 |
| DK1423357T3 (da) | 2007-01-15 |
| EP1423357B1 (en) | 2006-09-06 |
| DE60214569T2 (de) | 2007-05-03 |
| WO2003002524A2 (en) | 2003-01-09 |
| US20030176439A1 (en) | 2003-09-18 |
| CA2451206C (en) | 2011-02-01 |
| EP1423357A2 (en) | 2004-06-02 |
| PE20030133A1 (es) | 2003-04-08 |
| WO2003002524A3 (en) | 2004-03-11 |
| JP4231403B2 (ja) | 2009-02-25 |
| EP1270551A1 (en) | 2003-01-02 |
| JP2004530726A (ja) | 2004-10-07 |
| CY1105751T1 (el) | 2010-12-22 |
| US6706715B2 (en) | 2004-03-16 |
| ES2269750T3 (es) | 2007-04-01 |
| PT1423357E (pt) | 2006-12-29 |
| CA2451206A1 (en) | 2003-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU89202A (sh) | Faktor viia inhibitorni derivati (tio)uree, njihovo dobijanje i upotreba | |
| RS40404A (en) | Indole-2-carboxamides as factor xa inhibitors | |
| IL156588A0 (en) | Oxybenzamide derivatives as factor xa inhibitors | |
| MXPA03011022A (es) | Derivados de urea con actividad antiproteolitica. | |
| TW200505914A (en) | Pyrazole-derivatives as factor Xa inhibitors | |
| TW200510393A (en) | New indole derivatives as factor Xa inhibitors | |
| TW200510400A (en) | Indazole-derivatives as factor Xa inhibitors | |
| IL171843A (en) | TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS | |
| YU29702A (sh) | N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju | |
| TNSN05297A1 (en) | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
| TNSN05296A1 (en) | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
| TW200504027A (en) | Imidazole-derivatives as factor Xa inhibitors | |
| TW200716620A (en) | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors | |
| JO2467B1 (en) | New indole derivatives as an inhibitor of Xa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| HC | Change of company name or juridical status |